Yanhong Ni

3.2k total citations · 1 hit paper
97 papers, 2.4k citations indexed

About

Yanhong Ni is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yanhong Ni has authored 97 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 36 papers in Oncology and 28 papers in Cancer Research. Recurrent topics in Yanhong Ni's work include Head and Neck Cancer Studies (14 papers), RNA modifications and cancer (11 papers) and Cancer, Hypoxia, and Metabolism (11 papers). Yanhong Ni is often cited by papers focused on Head and Neck Cancer Studies (14 papers), RNA modifications and cancer (11 papers) and Cancer, Hypoxia, and Metabolism (11 papers). Yanhong Ni collaborates with scholars based in China, Australia and United States. Yanhong Ni's co-authors include Liang Ding, Yuxian Song, Qingang Hu, Xiaofeng Huang, Yayi Hou, Yue Jing, Yingchun Dong, Jianjian Ji, Xihu Yang and Xiaoyin Zhao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Yanhong Ni

92 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exosomal miR-146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin-1β-Primed Mesenchymal Stem Cells Against Sepsis

2017 383 citations Yuxian Song, Jianjian Ji et al. profile →

Peers

Countries citing papers authored by Yanhong Ni

Since Specialization

Citations

This map shows the geographic impact of Yanhong Ni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanhong Ni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanhong Ni more than expected).

Fields of papers citing papers by Yanhong Ni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanhong Ni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanhong Ni. The network helps show where Yanhong Ni may publish in the future.

Co-authorship network of co-authors of Yanhong Ni

This figure shows the co-authorship network connecting the top 25 collaborators of Yanhong Ni. A scholar is included among the top collaborators of Yanhong Ni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanhong Ni. Yanhong Ni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Application of Nanoformulations in the Treatment of Oral Cancer 2025 ·Small ·(unknown), (unknown), (unknown), Shibao Feng, Yuan Feng, Mimi Wan, (unknown), Yanhong Ni, Chun Mao	0
2	Role of LncRNA UCA1 in OSCC CAFs : PD ‐ L1 Upregulation and Tumor Progression 2025 ·Journal of Oral Pathology and Medicine ·(unknown), Mengxiang Zhao, Yong Fu, Xingxing Zhao, (unknown), Antonio Celentano, Liang Ding, Qingang Hu, Yanhong Ni	0
3	UCNPs@PVP‐Hemin‐GOx@CaCO₃ Nanoplatform for Ferroptosis Self‐Amplification Combined with Calcium Overload 2025 ·Advanced Healthcare Materials ·(unknown), (unknown), Runzhi Deng, Jiajia Meng, Lingxia Xu, Wenbo Zhao, Yanhong Ni, Chun Mao, Shirong Zhang	2
4	COMP promotes pancreatic fibrosis by activating pancreatic stellate cells through CD36-ERK/AKT signaling pathways 2024 ·Cellular Signalling ·Yi Wang, Haitao Li, Gang Liu, (unknown), Yanhong Ni, Jinghui Zeng, Lin Xia, (unknown), Dazhou Li, Wen Wang, Xiang‐Peng Zeng	3
5	Physicochemical behavior and ecological risk of biofilm-mediated microplastics in aquatic environments 2024 ·Aquatic Toxicology ·Ranran Zhou, Xirong Huang, Yanhong Ni, Zewei Ma, (unknown), Qijie Jin, Zhuhong Ding	3
6	Lipid droplets-related Perilipin-3: potential immune checkpoint and oncogene in oral squamous cell carcinoma 2024 ·Cancer Immunology Immunotherapy ·(unknown), Lingyun Liu, (unknown), Xiaoxin Zhang, Yuxian Song, Yue Jing, Yanhong Ni, Yi Wang, Zhiyong Wang, Liang Ding	6
7	Integrating clinical and genomic landscape analysis of perineural invasion identify ACTA1 as an oncogene for oral squamous cell carcinoma 2024 ·Frontiers in Cell and Developmental Biology ·Sheng Chen, Tongchao Zhao, Yuxian Song, Xiaofeng Huang, Yanhong Ni, Liang Ding, Yong Fu, Qingang Hu, Yi Wang	3
8	Development and validation of a prognostic nomogram for predicting cancer-specific survival in advanced endometrial carcinoma after surgery: a retrospective analysis of the SEER Database 2023 ·BMJ Open ·(unknown), (unknown), (unknown), Xiaoling Liang, (unknown), (unknown), (unknown), (unknown), Yanhong Ni, Peili Zhang, (unknown)	1
9	Oral tongue squamous cell carcinoma diagnosis from tissue metabolic profiling 2023 ·Oral Diseases ·Shuai Wang, Ke Li, (unknown), (unknown), Tao Zeng, (unknown), Liang Ding, Xiaofeng Huang, Antonio Celentano, Xihu Yang, Qingang Hu, Yanhong Ni	3
10	Prognostic impact of muscle invasion in buccal mucosa squamous cell carcinoma 2023 ·Oral Diseases ·(unknown), Shuai Wang, Wei‐xian Zhang, Feng Zhu, Lei Zhang, Sheng Chen, (unknown), (unknown), Xiaofeng Huang, Antonio Celentano, Yanhong Ni	0
11	Multiperspective quantitative tumor–stroma ratio reveals histological areas associated with poor outcomes in oral squamous cell carcinoma 2023 ·Cancer Medicine ·Shuai Wang, (unknown), Yan Wu, (unknown), Wei‐xian Zhang, Xiaofeng Huang, Tao Zeng, Sheng Chen, Xihu Yang, Yanhong Ni, Qingang Hu	7
12	Halofuginone inhibits tumor migration and invasion by affecting cancer-associated fibroblasts in oral squamous cell carcinoma 2022 ·Frontiers in Pharmacology ·Danni Wang, Mei Tian, Yong Fu, (unknown), Liang Ding, Xiaoxin Zhang, Yue Jing, Guowen Sun, Yanhong Ni, Yuxian Song	7
13	A novel iron oxychloride nanosheets-based multifunctional nanocomposites for synergistic cancer treatment 2021 ·Materials Today Communications ·Yan Xiang, Jie Yang, (unknown), Han Su, Guowen Sun, Yanhong Ni, Weibin Sun	1
14	Puerarin Ameliorates Caerulein-Induced Chronic Pancreatitis via Inhibition of MAPK Signaling Pathway 2021 ·Frontiers in Pharmacology ·Xiang‐Peng Zeng, Jinghui Zeng, Lin Xia, Yanhong Ni, (unknown), Dazhou Li, (unknown), Rong Wang, Wen Wang	14
15	Asparagine Synthetase-Mediated l-Asparagine Metabolism Disorder Promotes the Perineural Invasion of Oral Squamous Cell Carcinoma 2021 ·Frontiers in Oncology ·Yong Fu, Liang Ding, Xihu Yang, (unknown), Xiaofeng Huang, Lei Zhang, Sheng Chen, Qingang Hu, Yanhong Ni	18
16	Tumor-Infiltrating CD1a+ DCs and CD8+/FoxP3+ Ratios Served as Predictors for Clinical Outcomes in Tongue Squamous Cell Carcinoma Patients 2019 ·Pathology & Oncology Research ·Yanhong Ni, Xiao-Xin Zhang, (unknown), Xiaofeng Huang, Zhiyong Wang, Yang Yan, Yingchun Dong, Yue Jing, Yuxian Song, Yayi Hou, Zichun Hua, Qingang Hu	22
17	The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects 2017 ·Molecular Cancer Therapeutics ·Liang Ding, Jing Ren, Dongya Zhang, Yi Li, Xiaofeng Huang, Jianjian Ji, Qingang Hu, Hui Wang, Yanhong Ni, Yayi Hou	66
18	SIRT1 activator (SRT1720) improves the follicle reserve and prolongs the ovarian lifespan of diet-induced obesity in female mice via activating SIRT1 and suppressing mTOR signaling 2014 ·Journal of Ovarian Research ·Xiaoling Zhou, Jinjie Xu, Yanhong Ni, Xiaochun Chen, Hongxia Zhang, Xing‐Mei Zhang, Wei-Juan Liu, Lili Luo, Yu‐Cai Fu	68
19	Serum CCL2 and CCL3 as potential biomarkers for the diagnosis of oral squamous cell carcinoma 2014 ·Tumor Biology ·Liang Ding, Bing Li, Ying Zhao, Yifu Fu, Erling Hu, Qingang Hu, Yanhong Ni, Yayi Hou	26
20	siRNA targeting midkine inhibits gastric cancer cells growth and induces apoptosis involved caspase-3,8,9 activation and mitochondrial depolarization 2007 ·Journal of Biomedical Science ·Qingling Wang, Yahong Huang, Yanhong Ni, Hui Wang, Yayi Hou	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact